Stocks and Investing Stocks and Investing
Mon, February 27, 2023
Sun, February 26, 2023
Sat, February 25, 2023
Fri, February 24, 2023

Michael Ulz Maintained (ALNY) at Hold with Decreased Target to $205 on, Feb 24th, 2023


Published on 2024-10-28 01:52:17 - WOPRAI, Michael Ulz
  Print publication without navigation


Michael Ulz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Decreased Target from $210 to $205 on, Feb 24th, 2023.

Michael has made no other calls on ALNY in the last 4 months.



There are 7 other peers that have a rating on ALNY. Out of the 7 peers that are also analyzing ALNY, 3 agree with Michael's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Decreased Target to $143 on, Monday, January 23rd, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $210 on, Friday, October 28th, 2022
  • Jessica Fye of "JP Morgan" Maintained at Hold with Decreased Target to $200 on, Monday, October 24th, 2022


These are the ratings of the 4 analyists that currently disagree with Michael


  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $253 on, Friday, December 16th, 2022
  • Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $415 on, Wednesday, November 2nd, 2022
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $270 on, Friday, October 28th, 2022
  • Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $236 on, Friday, October 28th, 2022